Articles By Wayne Koberstein, Executive Editor

Companies To Watch: Landos Biopharma
Companies To Watch: Landos Biopharma Our company to watch this month is Landos Biopharma, which is aiming for better targeting and better delivery of treatments for GI and other autoimmune diseases.  Continue Reading...
  • Industry Explorers Blaze On: Anna Protopapas
    Industry Explorers Blaze On: Anna Protopapas

    Her mother was the first woman of her village in Cyprus to go to high school. Anna Protopapas shared her mother’s drive to bypass all barriers, and she now runs the biopharma company Mersana, after many years in the leadership of Millennium and Takeda.

  • Reata Pharmaceuticals: Return & Reach Beyond
    Reata Pharmaceuticals: Return & Reach Beyond

    Reata refused to take what seemed like a dead-end trial as a losing proposition. Instead, the company went to work mining the trial for the very insights that subsequently saved it.

  • Companies To Watch: CytoDyn
    Companies To Watch: CytoDyn

    CytoDyn’s expressed ambitions seem bold but reasonably free of hyperbole. It is only natural to hope for the best possible outcome here, considering the obvious need for new HIV and other immunological therapies.

  • Companies To Watch: AmpliPhi Biosciences
    Companies To Watch: AmpliPhi Biosciences

    AmpliPhi Biosciences is pushing bacteriophage-therapy development for drug-resistant infections — not to replace, but possibly to augment antibiotics.

  • Companies To Watch Roundup 2017
    Companies To Watch Roundup 2017

    We check in with the companies we profiled from this section in 2017 to see what has changed … if anything.

  • CYDAN: Mission In The Orphan Space
    CYDAN: Mission In The Orphan Space

    Cydan is using a new business model in which they challenge the ways companies dealt with orphan drugs in the past.

  • Your Bio Company’s Story: The Mechanics Of Clarity
    Your Bio Company’s Story: The Mechanics Of Clarity

    Here, I aim to offer some additional ideas for how companies can best describe themselves and their products — and how PR agents, journalists, and others might describe them — by achieving the opposite of hype: clarity.

  • Companies To Watch: Zavante
    Companies To Watch: Zavante

    This month’s Company To Watch is 10-person Zavante, which is challenging drug resistance with a retooled antibiotic and a broad mechanism of action.

  • PolarityTE: Beyond Cells, To Whole Tissue
    PolarityTE: Beyond Cells, To Whole Tissue

    In this series on "Life Science Leadership In Action," we discuss PolarityTE, which focuses on regenerating lost tissues in their original complex forms.

  • Industry’s Reflected Gold
    Industry’s Reflected Gold

    In my travels, I’ve especially noted three areas of unavoidable transformation due to forces quite beyond the industry’s control: women’s advocacy, the drug-pricing stalemate, and the new politics.

  • Industry Explorers Blaze On: Pat Andrews
    Industry Explorers Blaze On: Pat Andrews

    A look at the 26-year career of Pat Andrews, CEO of Boston Biomedical, who went from Big Pharma to small biotech.

  • Not a Bad Year, After All
    Not a Bad Year, After All

    Peter Meath, who heads the Life Science Group at J.P. Morgan’s Commercial Banking business, offers advice to novice entrepreneurs for turning a company’s novel science into a viable business.

  • Companies To Watch: Daré Bioscience
    Companies To Watch: Daré Bioscience

    Bridging to commercialization of women’s reproductive health products — starting with a novel contraceptive.

  • More from the Women of Biopharma — Full Measures of Progress
    More from the Women of Biopharma — Full Measures of Progress

    In the December 2017 issue’s article, “The Women of Biopharma — Will They Gain or Lose Ground in 2018?” we summarize the responses of those who chose to contribute as panelists in a “virtual roundtable” discussion. Here, as promised, we are posting their written responses in full.

More From Wayne Koberstein
Wayne Koberstein

Wayne Koberstein


Wayne Koberstein is a 30-year veteran of the publishing industry, with extensive experience in publishing, communications, and business development. Wayne has interviewed and profiled more than 300 top executives in pharmaceutical companies, as well as major regulatory and health care leaders, around the world. He has also created special media projects and conferences, in addition to serving widely as speaker, moderator, and advisor for industry meetings.